| Description | RBN-3143 is a potent and inhibitor of NAD+-competitive catalytic PARP14 (IC50= 4 nM). RBN-3143 inhibits ADP-ribosylation mediated by PARP14 and stabilizes PARP14 in cell lines. RBN-3143 exhibits research potential of lung inflammation. |
| In vivo | RBN-3143（5 μg；通过鼻腔给药）能够改善类固醇耐药性哮喘小鼠模型[1]。 |
| Target activity | PARP14:4 nM |
| molecular weight | 449.54 |
| Molecular formula | C22H28FN3O4S |
| CAS | 2360853-16-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 11.2 mg/mL (25.0 mM), Sonication and heating to 80℃ are recommended. |
| References | 1. Niepel M, et, al. The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models. European Respiratory Journal 2022 60: 4642. |